Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Exercise and NK Cell Regulation After IL-6R Blockade
NCT04616235Completed
- Sponsor
- Rigshospitalet
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Randomised, double-blind trial of tocilizumab, sponsored by Rigshospitalet. Primary endpoints: Kinetics and regulation of NK cells during and following acute exercise at 1 day and NK cell phenotype in response to acute exercise at 1 day. Started Mar 2021; status: completed.
02
Drugs
tocilizumab
Beyond the preview
Go deeper on NCT04616235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616235.